Biopharma Funds Regain Some Health

At least one fund is in the black, and several others moved closer to breakeven in October.

Illustration by II

Illustration by II

A number of biopharma hedge funds enjoyed a healthier October.

These were led by the Soleus Capital Master Fund, which moved back into the black after gaining 5 percent for the month. It is now up nearly 3 percent for the year, according to two investors.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.